Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Corporate Presentation AWOL
View:
Post by Spartrap on Jan 15, 2021 9:51am

Corporate Presentation AWOL

OK, it's rant time for me finally.. I guess I'm always a bit out of schedule:

What kind of company removes its Corporate Presentation, the essential tool for gathering first insights, right before and during a financing?! It's been AWOL and replaced by a placeholder since January 8 according to a Scarlet post.

Seriously, 8 days!

Where exactly, may I ask, are new investors supposed to gather informations about their new investment? That is completely unacceptable and amateurish!

And by the way, this resonates with the out-of-fashion, unattractive website, and e-mail alerts that only arrive one timeout of 3 (!!!). I agree with many here, to say that lots of changes are urgently needed in the communication department.

Comment by scarlet1967 on Jan 15, 2021 10:13am
Couldn't agree more, as per CFO he knows who will be the holders of millions of new shares? How is that possible? Now will all the new shareholders who have limited knowledge of this company they need to do whatever they can to stop them from flipping their holdings for a little premium.Some say the company's website is not important which is absolutely incorrect imo, They have been ...more  
Comment by scarlet1967 on Jan 15, 2021 2:09pm
This was posted here earlier, they put it on their Twitter account today with only few thousand followers, they need to use a well known platform so they can get decent exposure. https://www.linkedin.com/posts/theratechnologies-inc_capsules-entrepreneuriales-theratechnologies-activity-6755876418296659968-XVra
Comment by scarlet1967 on Jan 15, 2021 2:23pm
It was posted both on LinkedIn and Twitter, the Twitter account has only 90 followers?
Comment by SPCEO1 on Jan 15, 2021 2:43pm
Was the twitter version in English?
Comment by MHemorrhage on Jan 15, 2021 2:56pm
No english version - just the subtitles. That are illegible on half the slides' white background. Video was done by Montreal Invivo who appears to exclusively work in French.
Comment by scarlet1967 on Jan 15, 2021 2:56pm
On both platforms English and French.
Comment by scarlet1967 on Jan 15, 2021 2:58pm
Yes the content was subtitled but the introduction was both in English and French.
Comment by qwerty22 on Jan 15, 2021 12:51pm
You happy with the cancer protocol?
Comment by Spartrap on Jan 15, 2021 3:06pm
Yes, quite happy! It looks very straightforward, very well though out to me. If I had any reservations, that would be about the grouping of Gynecological cancers in a single basket.. Ovarian, endothelial and endometrial.. do they share enough similarities? That looks a bit odd to me intuitively, but maybe it's the case. Also, something I struggle to perfectly understand is the starting ...more  
Comment by qwerty22 on Jan 15, 2021 5:32pm
The CRO https://www.ppd.com/therapeutic-expertise/oncology-and-hematology/
Comment by qwerty22 on Jan 15, 2021 6:04pm
our PI wrote a book on ADCs and clinical trials https://ascopubs.org/doi/10.1200/EDBK_280775?url_ver=Z39.88-2003@rfr_id=ori:rid:crossref.org@rfr_dat=cr_pub%20%200pubmed The whole thing is super relevant and I think readable as long as you can get past the ADC as opposed to PDC factor (JFM).
Comment by qwerty22 on Jan 16, 2021 11:52am
FWIW I went chasing this issue. I found an abstract that helps with the mol weight issue. https://cancerres.aacrjournals.org/content/80/16_Supplement/2910.short It says "TH1902 at 8.75 mg/kg/week (equivalent to docetaxel dose of 3.75 mg/kg/week)" So my calculation starting dose at 30mg= docetaxel 12.9mg dose. You were pretty close. I also found the Simon 1997 ref, what it says ...more  
Comment by Spartrap on Jan 20, 2021 4:34pm
Thank you for digging out all those details, that's very helpful. So it appears we are in the right ballpark.. also, I just heard in the presentation that the dose doubling phase is indeed for the first 2 doses after the first (so: 30, 60, 120). That is just great! Also, reading your linked article about Taxotere Ph1, I noticed the following in the dicussion section: "As a matter of ...more  
Comment by qwerty22 on Jan 20, 2021 5:28pm
You'd have to have a pretty liberal definition of "tolerate" for that to make sense. I guess because it's reversible they might mean initially tolerable but not for long. I was just about to add a little to this side conversation also, but you said it all, I'll add my bit anyway. So with 540 being top dose of Th-1902 that's equivalent of 232 docetaxel. That's ...more  
Comment by juniper88 on Jan 20, 2021 6:21pm
My wife has had 9 cycles of Carboplatin and Taxol. The taxol dosage was 175mg/m2, which is standard. As for side effects, her neurophils went down but never so low as to postpone treatment, very slight neuropathy which dissappear by taking B6, and unfortunately all her hair fell out.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse